60 Degrees Pharmaceuticals (SXTP) CEO reports new common stock purchases

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals President and CEO Geoffrey Dow, who also serves as a director, reported buying additional common stock in December 2025. He acquired 9,350 shares on 12/10/2025 at $0.9504 per share and 3,613 shares on 12/11/2025 at $0.9184 per share. After these transactions, he directly owned 49,948 common shares of the company.

Insider Trade Summary

Net Buyer: 12,963 shares ($12,204)

Net Buy 2 txns

Insider DOW GEOFFREY S

Role President and CEO

Bought 12,963 shs ($12K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,613	$0.9184	$3K
Purchase	Common Stock	9,350	$0.9504	$9K

Holdings After Transaction: Common Stock — 49,948 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOW GEOFFREY S

(Last) (First) (Middle)

C/O 60 DEGREES PHARMACEUTICALS, INC.

1025 CONNECTICUT AVENUE NW SUITE 1000

(Street)

WASHINGTON DC 20036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
60 DEGREES PHARMACEUTICALS, INC. [ SXTP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		P		9,350	A	$0.9504	46,335	D
Common Stock	12/11/2025		P		3,613	A	$0.9184	49,948	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Geoffrey Dow	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 60 Degrees Pharmaceuticals (SXTP) report?

The company reported that President, CEO and director Geoffrey Dow acquired additional common stock in two transactions on 12/10/2025 and 12/11/2025.

How many 60 Degrees Pharmaceuticals (SXTP) shares did Geoffrey Dow purchase?

Geoffrey Dow purchased 9,350 common shares on 12/10/2025 and 3,613 common shares on 12/11/2025.

At what prices did the SXTP CEO buy common stock?

On 12/10/2025 he bought shares at $0.9504 per share, and on 12/11/2025 he bought shares at $0.9184 per share.

How many 60 Degrees Pharmaceuticals (SXTP) shares does Geoffrey Dow now directly own?

Following the reported transactions, Geoffrey Dow directly owned 49,948 shares of 60 Degrees Pharmaceuticals common stock.

What is Geoffrey Dow’s relationship to 60 Degrees Pharmaceuticals (SXTP)?

Geoffrey Dow is a director of the company and serves as its President and CEO.

Was this Form 4 for one reporting person or multiple insiders at SXTP?

The report indicates it was filed by one reporting person, Geoffrey Dow.